ECOG-1505

Trial

Clinical Trial Title

ECOG-1505

Trial Status

Open to Enrollment

Start Date

July 2, 2009

Location

Trial Type

Cancer (Oncology)

Specific Condition

Lung Cancer

Description

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (? 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

 

  • Patients must have undergone complete resection of their NSCLC (stage IB [≥ 4 cm] - IIIA [T2-3N0, T1-3N1, T1-3N2]) prior to enrollment
  • Patients must have had lobectomy, sleeve lo-bectomy, bi-lobectomy, or pneumonectomy. Mediastinal LN sampling must have been done at time of pre-operative mediastinoscopy or intraoperatively
  • Patients must not have received prior systemic chemotherapy at any time (see Section 3.6.1 for exceptions for non-malignant indications), or hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years of randomization.

IRB Number

IRB00006090

Notes

Sponsored by: ECOG Eastern Cooperative Oncology Group

Principal Investigator Name

Ian Schnadig, MD

Contact Name

Legacy Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Last Updated: Wednesday, September 18, 2013 01:26:50 PM